Deciphera Pharmaceuticals (NASDAQ:DCPH) and Calithera Biosciences (NASDAQ:CALA) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, profitability, valuation, earnings and institutional ownership.
Risk and Volatility
Deciphera Pharmaceuticals has a beta of 3.18, indicating that its stock price is 218% more volatile than the S&P 500. Comparatively, Calithera Biosciences has a beta of 2.31, indicating that its stock price is 131% more volatile than the S&P 500.
This table compares Deciphera Pharmaceuticals and Calithera Biosciences’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Institutional & Insider Ownership
57.4% of Deciphera Pharmaceuticals shares are held by institutional investors. Comparatively, 55.5% of Calithera Biosciences shares are held by institutional investors. 20.6% of Deciphera Pharmaceuticals shares are held by company insiders. Comparatively, 17.2% of Calithera Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
This is a breakdown of current recommendations for Deciphera Pharmaceuticals and Calithera Biosciences, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Deciphera Pharmaceuticals currently has a consensus target price of $44.00, indicating a potential upside of 87.63%. Given Deciphera Pharmaceuticals’ higher probable upside, analysts clearly believe Deciphera Pharmaceuticals is more favorable than Calithera Biosciences.
Valuation and Earnings
This table compares Deciphera Pharmaceuticals and Calithera Biosciences’ gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Deciphera Pharmaceuticals||N/A||N/A||-$99.85 million||($2.82)||-8.32|
|Calithera Biosciences||$22.25 million||10.84||-$54.63 million||($1.49)||-4.13|
Calithera Biosciences has higher revenue and earnings than Deciphera Pharmaceuticals. Deciphera Pharmaceuticals is trading at a lower price-to-earnings ratio than Calithera Biosciences, indicating that it is currently the more affordable of the two stocks.
Deciphera Pharmaceuticals beats Calithera Biosciences on 7 of the 11 factors compared between the two stocks.
Deciphera Pharmaceuticals Company Profile
Deciphera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. The company's lead drug candidate is DCC-2618, which is in Phase III trial for the treatment of gastrointestinal stromal tumors; and that is in Phase I trial for treating advanced systemic mastocytosis, gliomas, and other solid tumors. It is also developing immunokinase inhibitors comprising DCC-3014 that is in Phase I trial for treatment of solid tumors and hematologic malignancies; and Rebastinib, which is in Phase 1b trial to treat breast cancer, as well as to investigate in combination with chemotherapy and checkpoint inhibitors. The company was founded in 2003 and is headquartered in Waltham, Massachusetts.
Calithera Biosciences Company Profile
Calithera Biosciences, Inc., a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. Its lead product candidate is CB-839, an inhibitor of glutaminase, which is in Phase II clinical trial to treat solid tumors. The company also offers INCB001158, an oral inhibitor of arginase that is in Phase I/II clinical trial for the treatment of hematology and oncology. The company is also developing CB-280, an oral arginase inhibitor for the treatment of cystic fibrosis; and CB-708, an orally administered small molecule inhibitor of CD73. It has a license agreement with Mars, Inc. to develop and commercialize Symbioscience's portfolio of arginase inhibitors for use in human healthcare. The company also has clinical trial collaboration with Bristol-Myers Squibb Company to evaluate nivolumab in combination with CB-839. In addition, it has a collaboration and license agreement with Incyte Corporation for the research, development, and commercialization of INCB001158, a small molecule arginase inhibitor for the treatment of hematology and oncology. Calithera Biosciences, Inc. was founded in 2010 and is headquartered in South San Francisco, California.
Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.